Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2015

View Archived Issues

Initiation of clinical trial of TLR7 agonist GS-9620 in HIV-positive patients on ART

ISA Pharmaceuticals begins first phase I/II trial of Amplivant conjugates

Biogen Idec and Sobi report topline data from phase III Alprolix pediatric trial

Johnson & Johnson Health and Wellness Solutions formed to encourage well-being and quality of life

Cipher Pharmaceuticals acquires three dermatology products from Astion Pharma

New N-type calcium channel blockers disclosed by Janssen

Investigators at Duke University divulge new LpxC inhibitors

Pacira receives FDA complete response letter for Exparel sNDA

Cadila Healthcare patents new JAK inhibitors

Boehringer Ingelheim discloses new ENaC blockers

Russian and U.S. investigators present new adenosine A2A receptor antagonists

Phase II data lead to phase III initiation for HIV candidate BMS-663068

Abraxane approved by European Commission for first-line treatment of NSCLC

FDA accepts Alexion's BLA for asfotase alfa in hypophosphatasia for priority review

EMA committee recommends approval of Avastin plus chemotherapy for advanced cervical cancer

European Commission approves Xydalba for ABSSSI

Tenofovir alafenamide fumarate subject of several presentations at CROI

Shire submits NDA for lifitegrast for dry eye

Taiho seeks European approval for TAS-102 for metastatic colorectal cancer

FDA accepts for filing Xadago NDA

New clinical trial evaluates ZMapp for Ebola virus

Envelope-specific monoclonal antibodies offer a novel approach for the treatment of HIV infection

Torii gains rights from Japan Tobacco to market Gilead tenofovir alafenamide combinations in Japan

Boehringer Ingelheim files for approval of dabigatran antidote idarucizumab

FDA accepts sBLA for Yervoy in stage III melanoma

CHMP recommends approval of Humira for severe chronic plaque psoriasis in children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...